Caxton Associates (New York)’s Allogene Therapeutics ALLO Stock Holding History

Caxton Associates (New York)’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	$440K	Sell	206,380 -35,722	-15%	-$88.1K	0.01%	358
2024 Q3	$678K	Sell	242,102 -224,008	-48%	-$597K	0.03%	316
2024 Q2	$1.09M	Buy	466,110 +34,924	+8%	+$103K	0.04%	237
2024 Q1	$1.93M	Sell	431,186 -343,907	-44%	-$1.43M	0.11%	130
2023 Q4	$2.49M	Buy	775,093 +294,989	+61%	+$837K	0.13%	95
2023 Q3	$1.52M	Buy	480,104 +410,520	+590%	+$1.8M	0.21%	82
2023 Q2	$346K	Buy	69,584 +47,756	+219%	+$258K	0.05%	320
2023 Q1	$108K	Buy	+21,828	New	+$140K	0.02%	462
2022 Q2	–	Sell	-41,645	Closed	-$379K	–	551
2022 Q1	$379K	Buy	+41,645	New	+$434K	0.03%	317

Other funds holding ALLO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Caxton Associates (New York)'s ALLO Position: Q4 2024 in Review

Caxton Associates (New York) reduced its Allogene Therapeutics (ALLO) stake by 15% in Q4 2024, selling an estimated $88.1K and leaving 206,380 shares worth $440K. The position accounts for 0.01% of the portfolio, ranked #358.

Caxton Associates (New York) first reported a position in ALLO in Q1 2022 and has held it in 9 quarters since. The position peaked at $2.49M in Q4 2023. 174 funds tracked by Wall St. Rank hold ALLO as of Q4 2024.

Caxton Associates (New York) held 206,380 shares of Allogene Therapeutics worth $440K as of Q4 2024.
Caxton Associates (New York) sold 35,722 Allogene Therapeutics shares in Q4 2024, an estimated $88.1K.
Allogene Therapeutics made up 0.01% of Caxton Associates (New York)'s portfolio in Q4 2024, its #358 holding.
Caxton Associates (New York) first reported a position in Allogene Therapeutics in Q1 2022 and has held it in 9 quarters since.
Caxton Associates (New York)'s Allogene Therapeutics position peaked at $2.49M in Q4 2023.
174 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q4 2024.

Based on Caxton Associates (New York)'s 13F filing for Q4 2024, filed 14 Feb 2025.